Edward C. Mansley - Concepedia

Author

Edward C. Mansley

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

E MANSLEY1, E Mansley, Edward C Mansley, Edward C. Mansley, Edward Mansley

Publications

584

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military Academy Centers for Disease Control and Prevention University of Washington University of Southern California

About

Edward C. Mansley is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, economic evaluation, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	335
2	Business	1	1	16
3	Health Sciences	1	1	22
4	Law	1	1	22
5	Management	1	1	17

Edward C. Mansley

Publications

549

Citations

H-Index

Page 1

	Year	Citations
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part II Louis P. Garrison, Edward C. Mansley, Thomas A. Abbott, Value in Health Substance AbuseCost-effectiveness AnalysisHealth PolicyHealth EconomicsMedicine	2009	154
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report—Part I Joel W. Hay, Jim Smeeding, Norman V. Carroll, Value in Health Substance AbuseCost-effectiveness AnalysisHealth EconomicsHealth PolicyMedicine	2009	105
Colorectal Cancer Screening Attitudes and Practices in the General Population Walter L. Straus, Edward C. Mansley, Karen Gold, Journal of Public Health Management and Practice	2005	37
Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever John R. Wingard, Helen Leather, Craig A. Wood, American Journal of Health-System Pharmacy	2007	33
Do drug formulary policies reflect evidence of value? Peter J. Neumann, Pei‐Jung Lin, Dan Greenberg, PubMed	2006	31
Caspofungin versus amphotericin B for candidemia: A pharmacoeconomic analysis John R. Wingard, Craig A. Wood, Elizabeth Sullivan, Clinical Therapeutics Pharmacoeconomic AnalysisAntifungal AgentAntifungal AgentsPharmacologyMedicinal Fungi	2005	28
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report—Part III Edward C. Mansley, Norman V. Carroll, Kristina Chen, Value in Health Cost-effectiveness AnalysisHealth EconomicsHealth PolicyHealth Care ReimbursementCost-effectiveness Analyses	2009	26
Variation in Average Costs among Federally Sponsored State-Organized Cancer Detection Programs: Economies of Scale? Edward C. Mansley, Diane O. Duñet, Daniel May, Medical Decision Making	2002	24
Choosing the right battlefield for the war on drugs: an irrelevance result Stephen W.K. Chiu, Edward C. Mansley, John Morgan Economics Letters Substance AbuseSubstance UseDrug IntelligenceAddictionDrug Policy	1998	22
`Me-Too' Innovation in Pharmaceutical Markets Anupam B. Jena, John E. Calfee, Edward C. Mansley, Forum for Health Economics & Policy	2009	21

Page 1